Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that members of its management team will participate in two investor conferences in August and September 2026. President and Chief Executive Officer Dr. Seth Lederman will engage in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11 from 1:30 p.m. to 1:55 p.m. ET. Additionally, Dr. Lederman will hold one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 16.
These conferences provide Tonix with a platform to discuss its business strategy, recent developments, and pipeline progress with the investment community. The company's participation underscores its commitment to maintaining transparent communication with shareholders and potential investors.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on developing treatments for central nervous system (CNS) and immunology conditions with high unmet medical needs. The company's flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved and represents the first new treatment for fibromyalgia in over 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine treatments Zembrace® SymTouch® and Tosymra®.
Beyond its approved products, Tonix is actively exploring the full potential of TONMYA through Phase 2 clinical trials investigating its efficacy in major depressive disorder and acute stress disorder. The company's CNS pipeline also includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder. In the immunology space, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection.
It is important to note that Tonix's product development candidates are investigational drugs or biologics; their safety and efficacy have not yet been established, and they have not been approved for any indication. The announcements at these conferences will likely provide insights into the company's strategic direction and upcoming milestones, which could be of interest to investors tracking the biotech sector.
For more information about Tonix Pharmaceuticals and its latest news, visit the company's newsroom at https://ibn.fm/TNXP. The full press release can be accessed at https://ibn.fm/DKFAC.
